TIDMGWP

RNS Number : 5736W

GW Pharmaceuticals PLC

28 April 2016

GW Pharmaceuticals to Report Q2, Half-Year Financial Results and Host Conference Call on 5 May, 2016

London, UK, 28 Apr 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 May, 2016 its second quarter and half-year financial results for the period ending 31 March, 2016. GW will also host a conference call the same day at 9:00 a.m. EDT (2:00 p.m. BST). Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R) (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com

Enquiries:

 
 GW Pharmaceuticals plc 
 Stephen Schultz, VP Investor        917 280 2424 / 401 500 
  Relations (U.S.)                    6570 
 
 FTI Consulting (Media Enquiries) 
 Ben Atwell / Simon Conway           +44 20 3727 1000 
 FleishmanHillard (U.S. Media) 
                                     212 453 2382 / 917 697 
 Paddi Hurley / Adam Silverstein      9313 
 
 Peel Hunt LLP (UK NOMAD) 
 James Steel                         +44 20 7418 8900

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORQDLFLQZFLBBF

(END) Dow Jones Newswires

April 28, 2016 07:00 ET (11:00 GMT)

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Gw Pharmaceuticals Charts.
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Gw Pharmaceuticals Charts.